Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 19/20 | 0.65 |
| ▸ | MMP13 | P45452 | 17/20 | 0.65 |
| ▸ | MMP1 | P03956 | 5/20 | 0.62 |
| ▸ | MMP9 | P14780 | 5/20 | 0.62 |
| ▸ | MMP2 | P08253 | 9/20 | 0.53 |
| ▸ | MMP14 | P50281 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6263169 | 0.87 | ADAM17 (0.68) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6264365 | 0.87 | ADAM17 (0.66) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7357669 | 0.85 | MMP2 (0.69) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL3946153 | 0.85 | MMP2 (0.69) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6838381 | 0.85 | MMP13 (0.52) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6266622 | 0.84 | ADAM17 (0.85) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6263835 | 0.82 | ADAM17 (0.73) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6263929 | 0.80 | MMP2 (0.50) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6261988 | 0.79 | MMP2 (0.49) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL7040196 | 0.79 | ADAM17 (1.00) | ADAM17MMP13MMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6358980-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-03-19 | — | — | US | claimed |
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.